Axonics v. Medtronic: Federal Circuit Vacates & Remands in 511-Day Patent Appeal
Axonics, Inc. challenged five Medtronic patents covering rechargeable sacral neuromodulation and tissue-stimulating implant systems at the Court of Appeals for the Federal Circuit. The court vacated the lower decision and remanded the case, leaving the patentability dispute unresolved after 511 days of appellate proceedings.
Federal Circuit resets Medtronic's patent validity fight with Axonics
Axonics, Inc. initiated this appeal (No. 22-1533) on 14 March 2022 before the Court of Appeals for the Federal Circuit, challenging patentability determinations relating to five Medtronic patents: US7774069B2, US8457758B2, US3942535A, US8738148B2, and US3888260A. The patents collectively cover rechargeable demand-inhibited cardiac pacer and tissue stimulator technology, rechargeable sacral neuromodulation systems, and alignment indication for transcutaneous energy transfer — core IP underpinning Medtronic's implantable neuromodulation portfolio.
The Federal Circuit closed the case on 7 August 2023 with a verdict of 'Vacated and Remanded.' The recorded basis of termination is likewise 'Vacated and Remanded,' meaning the court found reversible error or insufficiency in the decision below and returned the matter for further proceedings without itself resolving the patentability merits. The specific grounds for vacatur are not detailed in the available public record.
The 511-day appellate timeline is consistent with a fully briefed Federal Circuit appeal involving multiple patents and complex patentability arguments. A vacatur and remand means neither party obtained a final merits ruling at this stage; the dispute over the validity of these five patents continues at the originating tribunal. The specific instructions given to the lower body on remand are not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Vacated and Remanded in 511 days
511 days from filing to close — a full appellate cycle at the Federal Circuit
US7774069B2 and four further Medtronic neuromodulation patents at issue
Any company developing or commercialising rechargeable implantable neuromodulators, sacral nerve stimulators, tibial nerve stimulators, or transcutaneous energy transfer systems for implantable devices should assess exposure against this five-patent Medtronic portfolio. The vacatur means validity is not settled — but the patents remain in force and enforceable during remand, making an FTO assessment both urgent and technically nuanced.
Official order — verbatim text
The Federal Circuit's 'Vacated and Remanded' disposition in Axonics v. Medtronic (No. 22-1533) indicates the court identified reversible error in the patentability determination below — whether legal, factual, or procedural — sufficient to nullify that ruling without entering its own merits judgment. Under Federal Circuit appellate review, factual findings from the Patent Trial and Appeal Board are reviewed for substantial evidence while legal conclusions are reviewed de novo; a vacatur suggests at least one of those standards was not met. The specific grounds are not detailed in the available public record. Both parties return to the originating forum without a final resolution on the validity of the five Medtronic neuromodulation patents.
Vacated and remanded: what the Federal Circuit's ruling means for both parties
What 'Vacated and Remanded' means at the Federal Circuit
A vacatur nullifies the decision under review — it is not an affirmance or a reversal on the merits. The Federal Circuit found the lower ruling legally insufficient or procedurally defective and returned the case for reconsideration. The originating tribunal must address the patentability questions again in light of the appellate court's guidance. No final validity determination was entered at this stage.
Lower ruling nullified; case continuesAxonics avoids an adverse ruling but gains no confirmed invalidity
The vacatur prevents an unfavourable lower decision from standing against Axonics, preserving the company's invalidity arguments for another round. However, Axonics did not secure a definitive finding that Medtronic's five neuromodulation patents are invalid. The competitive commercial pressure from those patents — and the risk of infringement liability — persists until the remand proceedings reach a final conclusion.
No invalidity confirmed; remand pendingMedtronic's patents survive — but validity remains in dispute
Medtronic retains its five issued patents covering rechargeable sacral neuromodulation and tissue stimulation systems. A vacatur does not invalidate those patents; they remain in force during the remand. However, the Federal Circuit's decision signals that the original patentability analysis was not upheld as written, and Medtronic must defend the patents' validity again in the proceedings below.
Patents in force; validity unresolvedOngoing IP uncertainty for the sacral neuromodulation device market
Five Medtronic patents central to rechargeable implantable neuromodulation and transcutaneous energy transfer remain under active validity challenge. Competitors and new entrants in the sacral neuromodulation space face continued uncertainty about the scope and enforceability of this portfolio. The remand prolongs that uncertainty, consistent with the high-stakes, multi-round nature of Federal Circuit patent litigation in the medical device sector.
Market uncertainty extendedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axonics, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Andrew James Isbester | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Kilpatrick Townsend & Stockton, LLP | Law Firm | Representing Axonics, Inc.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the implantable neuromodulation IP space
Forward-looking patent intelligence drawn from the Axonics–Medtronic dispute — covering portfolio activity, filing trends, and white-space opportunities in rechargeable sacral neuromodulation.
Medtronic's neuromodulation filing activity beyond the five disputed patents
Medtronic holds a deep portfolio in sacral and peripheral neuromodulation that extends well beyond the five patents challenged by Axonics. Tracking Medtronic's recent continuation filings, CIPs, and new applications in rechargeable implant architecture and transcutaneous charging reveals where the company is reinforcing its IP position — and which claim families Axonics (and other competitors) may face next.
Medtronic neuromodulation portfolioFiling trends in rechargeable implantable neuromodulation systems
Patent filings in miniaturised rechargeable sacral nerve stimulators and wireless implant charging have accelerated as the SNM market has grown. Mapping applicant concentration, claim evolution, and technology sub-clusters — including battery management, electrode arrays, and closed-loop feedback — reveals how the competitive IP landscape around Medtronic's disputed patents is being reshaped by new entrants and adjacent innovators.
SNM filing trendsAxonics' patent portfolio and defensive filing strategy
Axonics entered the sacral neuromodulation market with a miniaturised, MRI-compatible, rechargeable device and has been building its own IP position. Analysing Axonics' patent applications and granted patents — particularly in device miniaturisation, recharge management, and programming systems — indicates whether the company is developing offensive IP to counterbalance Medtronic's portfolio pressure or primarily relying on design-around strategies.
Axonics IP positionInnovation gaps near transcutaneous energy transfer alignment for implants
US7774069B2 covers alignment indication for transcutaneous energy transfer — a function critical to user-friendly wireless recharging of implants. Patent density mapping around this sub-technology reveals potential white space in coil alignment feedback, adaptive charging protocols, and patient wearable recharger design, suggesting R&D opportunities that sit adjacent to the contested claim space and may not be dominated by either party's current portfolio.
Wireless implant charging white spaceSimilar Federal Circuit appeals in implantable neuromodulation patent disputes
Explore Federal Circuit cases involving patentability challenges to implantable neuromodulation, sacral stimulation, and rechargeable medical device patents — the closest analogues to Axonics v. Medtronic.
What this case signals for the implantable neuromodulation IP landscape
A Federal Circuit vacatur over five foundational neuromodulation patents reshapes the competitive calculus for every player in sacral stimulation.
Validity uncertainty persists — FTO assessments for these five patents must account for remand
Any freedom-to-operate analysis touching US7774069B2, US8457758B2, US3942535A, US8738148B2, or US3888260A should note that patentability is still being litigated. An opinion treating these patents as definitively valid or invalid would be premature given the vacatur and ongoing remand proceedings.
Axonics–Medtronic rivalry signals sustained patent friction in sacral neuromodulation
The breadth of the challenged portfolio — spanning transcutaneous energy transfer, rechargeable pacer systems, and tissue stimulators — suggests the dispute is strategic, not opportunistic. Companies developing competing SNM or tibial nerve stimulation devices should monitor both the remand outcome and each party's broader filing activity in this technology space.
Axonics v Medtronic — key questions answered
The Federal Circuit vacated and remanded the lower patentability determination. The court found reversible error in the decision below but did not enter its own merits judgment on the validity of the five Medtronic patents. The specific grounds for vacatur are not detailed in the available public record. The case was closed on 7 August 2023 after 511 days.
Five Medtronic patents were at issue: US7774069B2 (alignment indication for transcutaneous energy transfer), US8457758B2 (rechargeable tissue stimulating system), US3942535A (rechargeable demand-inhibited cardiac pacer and tissue stimulator), US8738148B2, and US3888260A. They collectively cover rechargeable implantable neuromodulation and sacral stimulation technology.
Vacated and remanded means the Federal Circuit nullified the lower tribunal's decision — it found that ruling legally insufficient or procedurally defective — and returned the case for further proceedings. It is not an affirmance or a reversal on the merits. The originating body must reconsider the patentability questions in light of the appellate court's guidance.
Yes. A vacatur of the lower patentability decision does not invalidate the patents. US7774069B2, US8457758B2, US3942535A, US8738148B2, and US3888260A remain issued and in force. Their validity is disputed and will be addressed again in the remand proceedings. Companies assessing FTO exposure against these patents should treat them as enforceable pending the remand outcome.
Axonics was represented by Andrew James Isbester of Kilpatrick Townsend & Stockton, LLP. Medtronic was represented by Naveen Modi of Paul Hastings, LLP. The appeal was decided by the Court of Appeals for the Federal Circuit.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.